cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Avrobio Inc
11 own
15 watching
Current Price
$1.56
$0.02
(1.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
52.91M
52-Week High
52-Week High
1.93000
52-Week Low
52-Week Low
0.56000
Average Volume
Average Volume
0.28M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization52.91M
icon52-Week High1.93000
icon52-Week Low0.56000
iconAverage Volume0.28M
iconDividend Yield--
iconP/E Ratio--
What does the Avrobio Inc do?
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company s product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Avrobio Inc make?
News & Events about Avrobio Inc.
Business Wire
6 months ago
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled Orphan Neuro Corporate Panel at Cowens 43rd Annual Health...
Zolmax
1 year ago
AVROBIO, Inc. (NASDAQ:AVRO Get Rating) Investment analysts at Wedbush issued their Q1 2023 earnings per share estimates for AVROBIO in a report issued on Tuesday, May 10th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.29) per share for the quarter. Wedbush...
Business Wire
1 year ago
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the companys common stock to one...
Ticker Report
1 year ago
Wall Street analysts predict that AVROBIO, Inc. (NASDAQ:AVRO Get Rating) will report earnings of ($0.71) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for AVROBIOs earnings, with estimates ranging from ($0.76) ...
Frequently Asked Questions
Frequently Asked Questions
What is Avrobio Inc share price today?
plus_minus_icon
Can Indians buy Avrobio Inc shares?
plus_minus_icon
How can I buy Avrobio Inc shares from India?
plus_minus_icon
Can Fractional shares of Avrobio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Avrobio Inc stocks?
plus_minus_icon
What is today’s traded volume of Avrobio Inc?
plus_minus_icon
What is today’s market capitalisation of Avrobio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Avrobio Inc?
plus_minus_icon
What percentage is Avrobio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Avrobio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.56
$0.02
(1.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SOLID BIOSCIENCES INC
SOLID BIOSCIENCES INC
$2.60
$-0.15 (-5.45 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$0.96
$0.06 (6.97 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.35
$-0.02 (-0.84 %)
Gritstone Oncology Inc
Gritstone Oncology Inc
$1.20
$0.01 (0.84 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SOLID BIOSCIENCES INC
SOLID BIOSCIENCES INC
$2.60
$-0.15 (-5.45 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$0.96
$0.06 (6.97 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.35
$-0.02 (-0.84 %)
Gritstone Oncology Inc
Gritstone Oncology Inc
$1.20
$0.01 (0.84 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00